Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Bristol Myers reported that Sotyktu maintained efficacy through 104 weeks in the late-stage POETYK PsA-2 trial, with no new safety signals; serious adverse events and treatment discontinuations occurred in 12.6% and 7.6% of 604 treated patients, respectively. Sotyktu revenue rose 24% year over year to $156 million in H1 2026, and its recent psoriatic-arthritis approval expands BMY's immunology growth opportunity. Further upside depends on late-2026 SLE trial data, while competition remains significant from Amgen's Otezla and Takeda's investigational TYK2 inhibitor zasocitinib.

Analysis

The read-through for BMY is strategically positive but financially immaterial near term: the product’s current annualized sales run-rate is too small to offset the company’s broader loss-of-exclusivity and earnings-decay concerns. The investable implication is not a material 2026 EPS revision; it is whether prescribers and payers view the durability profile as sufficient to support sustained share gains in an oral immunology market. That would improve the probability of a multi-year growth asset rather than alter the next quarterly print.

The key caveat is that long-term extension results are subject to survivor and discontinuation bias; they are less useful for proving differentiation versus entrenched therapies than a clean head-to-head efficacy, persistence, or access advantage. AMGN’s Otezla retains commercial inertia, while TAK’s next-generation TYK2 entrant could pressure BMY’s eventual net price and force higher patient-support spending. Consequently, stronger utilization may initially expand gross sales faster than net sales and limit incremental margin contribution.

BMY’s valuation discount can persist despite favorable immunology news because the market needs evidence that growth products can cover the post-2026 earnings slope. The more consequential 1-3 month catalyst is late-2026 lupus data: success would reframe Sotyktu from a niche psoriasis/PsA asset into a platform opportunity, while a miss would remove the principal multiple-expansion narrative. Consensus appears too willing to extrapolate extension data into broad commercial superiority; the appropriate signal to monitor is sequential prescription growth and gross-to-net trends, not trial durability alone.

Key Decisions for Investors

• Maintain or initiate a modest 3-6 month long BMY position only on weakness; underwrite it as a valuation-plus-late-2026 lupus catalyst trade rather than an immediate PsA sales trade. Target a 10-15% upside from multiple stabilization and estimate resilience, with thesis invalidation if management reduces growth-portfolio guidance or 2027 EPS expectations deteriorate further.
• Use defined-risk upside exposure for the lupus readout: buy BMY calls expiring 1-2 months after expected data only if implied volatility remains below the historical range for major pipeline events. Avoid an outright large equity overweight because a negative study can reinforce the structural earnings-decline narrative.
• Monitor quarterly Sotyktu net-sales growth, formulary access, and discontinuation/persistence disclosures. If sequential growth slows materially despite the new indication, treat the data release as non-monetizable and exit catalyst exposure rather than averaging down.
• Do not short AMGN solely on this development. Otezla displacement is likely gradual, and AMGN’s earnings sensitivity to a single immunology competitor is limited; a cleaner relative trade would be long BMY versus a broad large-cap pharma basket only if upcoming data improve the probability of durable replacement revenue.